Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

Table 4 Immunogenicity of trivalent vaccine formulations

Vaccine test article	Formulation ID	Dose (by SRID)	H3/Perth GMT		H1N1 GMT*		B/Brisbane GMT
			Day 21	Day 42	Day 21	Day 42	Day 21	Day 42
A/Brisbane/10/2007 (H3N2)	2008-2009 rHA Formulation	3.0 μg/HA	19.1	63.5	183.8	670.3	38.2	442.2
B/Brisbane/60/2008		3.0 μg/HA	19.1	63.5	183.8	670.3	38.2	442.2
A/Brisbane/59/2007 (H1N1)		0.3 μg/HA	7.2	9.5	66.5	403.2	13.2	96.2
A/Perth/16/2009 (H3N2)	2010-2011 rHA Formulation	3.0 μg/HA	237.8	2560.0	226.3	1403.9^†	29.7	735.2
B/Brisbane/60/2008		3.0 μg/HA	237.8	2560.0	226.3	1403.9^†	29.7	735.2
A/California/07/2009 (H1N1)		0.3 μg/HA	121.8	1612.7	115.8	670.3	8.7	87.7
A/Victoria/210/2009 (H3N2)	2010-2011 Commercial Split Virion Vaccine (FluLaval® Lot # AFLLA599BA)	3.0 μg/HA	477.9	3079.7	211.1	557.1	45.9	403.2
B/Brisbane/60/2008		3.0 μg/HA	477.9	3079.7	211.1	557.1	45.9	403.2
A/California/07/2009 (H1N1)		0.3 μg/HA	152.7	1280.0	83.8	242.5	14.5	57.9

HAI titers were measured on serum samples collected 21 days after immunizations (Day 21 = one immunization; Day 42 = two immunizations) for the respective vaccine components and the geometric mean titer (GMT) calculated.
*HAI titers generated using matching H1N1 virus strains. ^† Statistically different (P < 0.01) from A/California commercial vaccine high dose group.

ISSN: 1472-6750